TYRUKO Drug Profile
Summary for Tradename: TYRUKO
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 1 |
Pharmacology for TYRUKO
| Mechanism of Action | Integrin Receptor Antagonists |
| Established Pharmacologic Class | Integrin Receptor Antagonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for TYRUKO Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for TYRUKO Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for TYRUKO Derived from Patent Text Search
No patents found based on company disclosures
Tyruko is the first U.S.-approved biosimilar to Tysabri (natalizumab), creating a lower-cost competitor in a high-value multiple sclerosis and Crohn's disease market. FDA approved Tyruko, or natalizumab-sztn, in August 2023, and Sandoz launched it in the United States in 2024. Its commercial trajectory depends on payer coverage, neurologist and gastroenterologist adoption, infusion-center economics, patient-support services, and the ability to convert patients from Biogen's Tysabri without disrupting treatment continuity. Sandoz does not disclose Tyruko revenue separately, so product-level sales and profitability cannot be independently quantified from public filings.
TYRUKO Market Dynamics, Financial Trajectory, Patent Position, and Competitive Outlook
What is Tyruko and who manufactures it?
Tyruko is the U.S. brand name for natalizumab-sztn, a biosimilar to Biogen's Tysabri, or natalizumab. Sandoz markets Tyruko in the United States, while Polpharma Biologics developed the biosimilar and has been associated with its manufacturing and development program. The product is administered by intravenous infusion and is approved for:
- Relapsing forms of multiple sclerosis in adults.
- Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to conventional therapies or TNF-alpha inhibitors.
Tyruko uses the same therapeutic target as Tysabri. Natalizumab binds the alpha-4 subunit of integrins and inhibits leukocyte migration across the blood-brain barrier and intestinal endothelium. Its principal clinical risk is progressive multifocal leukoencephalopathy, or PML, which requires risk-management controls and patient monitoring.
The FDA approved Tyruko on August 24, 2023, under the abbreviated 351(k) biosimilar pathway. The agency concluded that Tyruko is highly similar to Tysabri and has no clinically meaningful differences in safety, purity, and potency for the approved indications [1].
| Product | Active ingredient | Reference product | Manufacturer or marketer | FDA status |
|---|---|---|---|---|
| Tyruko | Natalizumab-sztn | Tysabri | Sandoz; Polpharma Biologics development relationship | FDA-approved biosimilar |
| Tysabri | Natalizumab | Reference biologic | Biogen | FDA-approved reference product |
When did Tyruko receive FDA approval and launch commercially?
FDA approved Tyruko in 2023, but U.S. commercial access followed later. Sandoz announced the U.S. launch in 2024, positioning Tyruko as the first natalizumab biosimilar available to American patients [2].
The launch timing reflects the difference between regulatory approval and commercial readiness. Biosimilar commercialization requires:
- Manufacturing scale-up and supply validation.
- Payer contracting.
- Infusion-site distribution.
- Patient-support infrastructure.
- Risk-management compliance.
- Inventory and substitution protocols.
- Provider education on switching and treatment continuity.
Tyruko is distributed through the Tysabri risk-management environment. Natalizumab prescribing and dispensing are subject to the FDA's TOUCH prescribing program, which limits treatment to authorized prescribers, infusion sites, and pharmacies. A biosimilar entrant must operate within that framework rather than compete solely through a conventional retail-pharmacy model [3].
How large is the Tysabri market that Tyruko is targeting?
Tysabri is one of Biogen's largest products and has generated approximately $2 billion annually in recent years. Biogen reported Tysabri revenue of approximately $2.1 billion in 2022 and approximately $2.0 billion in 2023, with reported sales affected by foreign exchange, pricing, and volume changes [4].
| Fiscal year | Approximate Tysabri revenue | Commercial implication |
|---|---|---|
| 2022 | About $2.1 billion | Large established reference-product base |
| 2023 | About $2.0 billion | Continued high-value franchise before broad biosimilar erosion |
| 2024 | Roughly $1.9 billion based on Biogen reporting | Early period of U.S. biosimilar competition and market pressure |
Tysabri revenue is not the same as the addressable U.S. market for Tyruko. The target market is narrower because:
- Tysabri sales include markets where Tyruko is not approved or not commercially available.
- Some patients and physicians may prefer the reference product.
- Payers may impose different coverage rules for new starts and existing patients.
- Infusion providers may have contracts that favor one product.
- Biosimilar uptake in specialty immunology can be slower than uptake for hospital-administered oncology products.
The commercial opportunity remains substantial because natalizumab is a chronic therapy with recurring infusions and high annual treatment costs. Even modest U.S. share can produce meaningful revenue for a biosimilar supplier.
What is the financial trajectory for Tyruko?
Sandoz has not publicly reported Tyruko revenue as a separate line item. The company reports performance by broader business segments and product categories, including biosimilars. This prevents a precise public calculation of Tyruko sales, gross margin, market share, or contribution to Sandoz's earnings.
The likely financial trajectory has four stages:
| Stage | Timing | Financial characteristics |
|---|---|---|
| Regulatory preparation | 2023 to early 2024 | Development, regulatory, supply-chain, and launch costs with limited product revenue |
| U.S. launch | 2024 | Initial revenue ramp, contracting costs, and low manufacturing utilization |
| Share expansion | 2025 onward | Better utilization, payer wins, repeat infusion demand, and improved contribution margin |
| Mature competition | Longer term | Price pressure, possible additional natalizumab biosimilars, and lower net price |
Tyruko's economics are likely to be stronger than those of a low-cost commodity generic because biologic production requires specialized cell culture, purification, quality testing, cold-chain logistics, and regulatory oversight. At the same time, biosimilars generally require lower clinical-development costs than an original biologic, which can improve capital efficiency.
Sandoz's economic objective is likely to combine:
- Gross margin from recurring biologic treatment.
- Cross-selling through established specialty and infusion channels.
- Portfolio density in immunology and multiple sclerosis.
- Manufacturing utilization across a broader biosimilar platform.
- Contracting leverage with national and regional payers.
Product-level profitability will depend heavily on the net price discount. A visible list-price reduction does not necessarily equal an equivalent reduction in payer net cost because rebates, administrative fees, distribution margins, and site-of-care economics affect the final price.
How does Tyruko compare with Tysabri commercially?
Tyruko's principal competitive advantage is price and payer leverage. Tysabri's principal advantages are brand familiarity, long-term clinical experience, established patient-support systems, and incumbent relationships with infusion sites and prescribers.
| Commercial factor | Tyruko | Tysabri |
|---|---|---|
| Regulatory status | Biosimilar | Reference biologic |
| Clinical evidence | Biosimilar analytical, pharmacokinetic, and clinical evidence | Full originator development program |
| Brand familiarity | Lower | High |
| Price position | Expected discount to reference product | Premium reference-product pricing |
| Distribution | Requires specialty and infusion channels | Established national infrastructure |
| Switching barrier | Provider and patient acceptance | Incumbent continuity |
| Payer leverage | Potential formulary preference | May rely on rebates and established contracts |
| Safety monitoring | TOUCH-related controls | TOUCH-related controls |
Tyruko will compete most effectively where payers actively encourage biosimilar use, infusion providers retain part of the economic benefit, and physicians can initiate new patients on the biosimilar without administrative friction.
What patents protect Tyruko and Tysabri?
Tyruko is a biosimilar and does not have a separate Orange Book patent estate equivalent to a small-molecule generic. FDA's Orange Book principally covers approved drug products and associated patents for conventional drug applications. Reference biologic patent information is handled through the biologics patent-disclosure and litigation framework rather than the ordinary Orange Book process.
The main legal issues are:
- Patent protection for natalizumab composition, formulations, manufacturing methods, and dosing.
- Biogen's reference-product patent rights.
- The statutory patent-exchange process under the Biologics Price Competition and Innovation Act.
- Any settlement, license, or launch agreement between Biogen and the biosimilar sponsor.
- Product-specific protection in the United States, European Union, and other markets.
The key commercial protection for Tysabri is no longer a single basic composition patent. The product has been marketed for many years, so the relevant barriers are more likely to involve formulation, manufacturing, dosing, device or administration, and regulatory exclusivity claims.
Public FDA approval does not establish that Tyruko is interchangeable with Tysabri. Biosimilarity and interchangeability are different regulatory concepts. Biosimilarity supports reliance on the reference product's data, while interchangeability may allow pharmacy-level substitution under applicable state law, subject to the product's FDA designation and state substitution rules [1].
Does Tyruko face Paragraph IV challenges or biosimilar litigation?
Paragraph IV challenges apply primarily to abbreviated new drug applications for small-molecule drugs under the Hatch-Waxman Act. Tyruko was approved under the 351(k) biologics pathway, so the relevant process is the BPCIA patent-exchange framework rather than a conventional Paragraph IV certification.
No major publicly disclosed Tyruko litigation or settlement with Biogen is established in the cited public record. The absence of a disclosed lawsuit does not eliminate patent risk. Biosimilar sponsors can launch after resolving patent issues, reaching a license arrangement, or determining that asserted patents do not block commercialization.
For investors and competitors, the relevant diligence points are:
- Whether Biogen has asserted or licensed any remaining patents.
- Whether Tyruko's commercial launch is subject to a negotiated date.
- Whether future biosimilar applicants have different launch positions.
- Whether manufacturing or process patents create operational constraints.
- Whether European or U.S. litigation produces different launch outcomes.
What market forces will determine Tyruko uptake?
Payer coverage and formulary placement
Payers can accelerate adoption through preferred placement, lower patient cost sharing, prior-authorization rules, and mandatory use of the lowest-net-cost product for new starts. They can also slow adoption by preserving reference-product access or requiring physician documentation for switching.
Physician and patient acceptance
Multiple sclerosis and Crohn's disease patients may be reluctant to switch a stable therapy, particularly when the reference product has years of clinical experience. New-patient initiation is usually an easier entry point than forced conversion of established patients.
Infusion economics
Tyruko is administered in an infusion setting. The economic decision therefore involves the drug acquisition price, reimbursement, site-of-care costs, nursing resources, chair time, and patient-support services. A discount that benefits the payer may not create a sufficient incentive for the infusion provider unless reimbursement rules align.
PML monitoring and risk-management continuity
The product's PML risk makes operational execution important. Providers must maintain appropriate patient enrollment, monitoring, dosing intervals, and infusion-site procedures. A biosimilar that offers reliable supply and clear support programs can reduce adoption friction.
Competitive entry
Tyruko's first-mover position is commercially valuable, but additional natalizumab biosimilars could compress prices and reduce share. The market may evolve from a reference-product-versus-biosimilar contest into a multi-biosimilar contracting market.
What generic and biosimilar launch scenarios exist for Tyruko?
Base case
Tyruko gains share primarily among new starts and price-sensitive payer contracts. Tysabri retains a large share of stable patients. Sandoz generates a gradual revenue increase with improving manufacturing utilization.
Upside case
Large payers designate Tyruko as preferred, infusion providers accept the product, and physicians adopt switching protocols. Share growth accelerates, producing stronger revenue and margin contribution.
Downside case
Payers preserve Tysabri coverage, physicians resist switching, or operational issues limit supply. Tyruko remains a niche product despite regulatory approval, and net pricing falls before volume reaches scale.
Competitive erosion case
One or more additional natalizumab biosimilars enter with deeper discounts. Tyruko maintains meaningful share through early launch, supply reliability, and Sandoz's commercial infrastructure, but revenue per treatment declines.
What is the geographic coverage for Tyruko?
Tyruko's strongest disclosed commercial importance is in the United States, where it entered a large Tysabri market under the FDA biosimilar framework. European and other international markets use separate regulatory and commercial pathways. Approval, naming, substitution, patent status, and reimbursement differ by jurisdiction.
Geographic expansion depends on:
- Local biosimilar approval.
- Reference-product exclusivity.
- Patent and settlement outcomes.
- National reimbursement decisions.
- Hospital and infusion procurement.
- Pharmacovigilance requirements.
- Local manufacturing and supply rules.
U.S. launch performance should not be extrapolated directly to Europe. European biosimilar adoption has generally been more payer-directed in many markets, while U.S. adoption depends more heavily on commercial contracting, benefit design, and site-of-care incentives.
How strong is the Tyruko competitive position?
Tyruko has a strong first-mover position but not an unassailable one. Its advantages are regulatory precedent, early commercial availability, the size of the Tysabri franchise, and Sandoz's established biosimilar infrastructure. Its weaknesses are the limited public visibility into product-level revenue, the complexity of natalizumab risk management, and the potential for additional biosimilar competition.
| Factor | Assessment |
|---|---|
| Regulatory differentiation | High as the first U.S. natalizumab biosimilar |
| Addressable market | Large, supported by approximately $2 billion annual Tysabri sales |
| Switching friction | High because treatment continuity and PML monitoring matter |
| Pricing power | Moderate at launch, likely lower with additional entrants |
| Manufacturing barrier | Meaningful due to biologic production and quality controls |
| Patent barrier | Jurisdiction-specific and dependent on remaining claims or agreements |
| Revenue visibility | Limited because Sandoz does not disclose Tyruko sales separately |
| Long-term outlook | Positive volume opportunity with uncertain net pricing |
Key Takeaways
- Tyruko is natalizumab-sztn, the first FDA-approved biosimilar to Tysabri.
- Sandoz launched Tyruko in the U.S. in 2024 after FDA approval in August 2023.
- The target reference-product market generates approximately $2 billion in annual Tysabri revenue.
- Sandoz does not disclose Tyruko revenue separately, preventing a precise product-level financial forecast.
- Uptake will depend on payer formulary decisions, infusion-site economics, physician confidence, and patient willingness to switch.
- Tyruko operates under the BPCIA biosimilar framework, not a conventional Paragraph IV generic pathway.
- The main commercial risks are slow switching, limited payer incentives, manufacturing constraints, and future natalizumab biosimilar competition.
- The main opportunity is recurring biologic revenue from a large chronic-treatment market with a high-value reference product.
FAQs About Tyruko
Is Tyruko cheaper than Tysabri?
Tyruko is intended to compete at a discount to Tysabri, but the actual net price depends on payer contracts, rebates, distribution terms, and infusion-site reimbursement.
Is Tyruko interchangeable with Tysabri?
Biosimilarity does not automatically establish interchangeability. Substitution rights depend on the FDA designation and applicable state pharmacy laws.
Can patients switch from Tysabri to Tyruko?
A switch may be clinically appropriate when directed by the treating physician and permitted by payer and product protocols. The decision must account for treatment continuity, monitoring, and PML risk-management requirements.
Does Tyruko have its own Orange Book listing?
Tyruko is a biologic approved under the 351(k) pathway. Its legal and patent framework differs from the conventional Orange Book and Paragraph IV system used for small-molecule generics.
What would hurt Tyruko's revenue growth?
The largest risks are weak payer preference, limited switching from Tysabri, lower-than-expected physician adoption, infusion-channel resistance, supply interruptions, and price competition from additional natalizumab biosimilars.
References
- U.S. Food and Drug Administration. (2023). FDA approves first biosimilar to Tysabri to treat multiple sclerosis and Crohn's disease. https://www.fda.gov
- Sandoz. (2024). Sandoz launches Tyruko, the first and only biosimilar to Tysabri, in the United States. https://www.sandoz.com
- Biogen. (2024). Tysabri prescribing information and TOUCH prescribing program materials. https://www.tysabri.com
- Biogen Inc. (2024). 2023 annual report. https://investors.biogen.com
More… ↓
